CAVEATS IN INTERPRETING AND COMPARING LONG-TERM EFFICACY IN BIOLOGIC STUDIES FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS

被引：0

作者：

Langley, Richard G. ^{[1
]}

Egeberg, Alexander ^{[2
]}

Gooderham, Melinda ^{[3
,4
]}

Bissonnette, Robert ^{[5
]}

Ringuet, Julien ^{[6
]}

Kalia, Sunil ^{[7
]}

Park-Wyllie, Laura ^{[8
]}

Abbarin, Nastaran ^{[8
]}

Tran, Diana ^{[9
]}

Zara, Anthony ^{[9
]}

Yang, Ya-Wen ^{[10
]}

Strober, Bruce ^{[11
,12
]}

机构：

[1] Dalhousie Univ, Halifax, NS, Canada

[2] Bispebjerg Hosp, Copenhagen, Denmark

[3] SKiN Ctr Dermatol & Prob Med Res, Kingston, ON, Canada

[4] Queens Univ, Kingston, ON, Canada

[5] Innovaderm Res Inc, Montreal, PQ, Canada

[6] Ctr Rech Dermatol Quebec Metropolitain CRDQ, Quebec City, PQ, Canada

[7] Univ British Columbia, Vancouver, BC, Canada

[8] Janssen Inc, Toronto, ON, Canada

[9] EVERSA NA, Burlington, ON, Canada

[10] Johnson & Johnson, Janssen Pharmaceut Co, Titusville, NJ USA

[11] Cent Connecticut Dermatol Res, Cromwell, CT USA

[12] Yale Univ, New Haven, CT USA

来源：

ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P-031

引用

页数：102

共 50 条

[1] Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasis
Langley, Richard G.
Egeberg, Alexander
Gooderham, Melinda
Bissonnette, Robert
Ringuet, Julien
Kalia, Sunil
Park-Wyllie, Laura
Abbarin, Nastaran
Tran, Diana
Zara, Anthony
Yang, Ya Wen
Strober, Bruce
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
[2] Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
Kimball, A. B.
Gordon, K. B.
Fakharzadeh, S.
Yeilding, N.
Szapary, P. O.
Schenkel, B.
Guzzo, C.
Li, S.
Papp, K. A.
BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04)
[3] Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
Zheng, Jianfeng
Chen, Wenjuan
Yi, Xuemei
Yu, Ning
Ding, Yangfeng
Gao, Yunlu
FRONTIERS IN MEDICINE, 2023, 10
[4] Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis
Umezawa, Y.
Nakagawa, H.
Niiro, H.
Ootaki, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (11) : 1957 - 1960
[5] A network meta-analysis of long-term efficacy and safety of treatments for moderate-to-severe plaque psoriasis
Armstrong, A.
Soliman, A.
Betts, K.
Wang, Y.
Gao, Y.
Stakias, V.
Puig, L.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E33 - E33
[6] Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis
Toth, Darryl P.
Papp, Kim
Gratton, David
DERMATOLOGIC THERAPY, 2008, 21 : S6 - S14
[7] Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis
Lynde, Charles
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 : 1 - 3
[8] Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data
Rustin, M. H. A.
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 3 - 11
[9] Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis
Langley, R
Leonardi, C
Toth, D
Chen, D
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
[10] A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis
Yifan Hu
Zeyu Chen
Yu Gong
Yuling Shi
Clinical Drug Investigation, 2018, 38 : 191 - 199

← 1 2 3 4 5 →